Page 1

July 12 , 2021 poxel Poxel Announces New Strategic Direction with Increasing Focus on Rare Metabolic Diseases Following Recent Achievements • Following the recent approval of TWYMEEGⓇ ( Imeglimin ) in Japan and associated potential future revenues , Poxel to accelerate and expand rare metabolic disease programs leveraging existing platforms and proven capabilities • Poxel to advance its deuterated thiazolidinediones ( dTZD ) and direct adenosine monophosphate - activated protein kinase ( AMPK ) activator platforms in rare metabolic diseases with initiation of PXL065 and PXL770 Phase 2a clinical Proof- of - Concept ( POC ) studies in X - linked adrenoleukodystrophy ( ALD ) in early 2022 ; data expected in Q4 2022 • Continued commitment to non - alcoholic steatohepatitis ( NASH ) through PXL065 DESTINY Phase 2 trial with results expected in Q3 2022 ; reassessment of PXL770 future development in NASH pending results from PXL065 Phase 2 trial and both Phase 2a POC studies in ALD • Webcast and conference call on Monday , July 12 , at 6:00 pm CEST ( in French ) , 1:15 pm ET ( in English ) LYON , France -- ( BUSINESS WIRE ) -- POXEL SA ( Euronext – POXEL - FR0012432516 ) , a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology , including non - alcoholic steatohepatitis ( NASH ) and rare disorders , today announced a new strategic direction to focus its pipeline on high value , rare metabolic indications and NASH , with the goal of creating pipeline synergies , maximizing resources , and driving shareholder value . " Based on the recent approval of TWYMEEGⓇ ( Imeglimin ) in Japan with the associated infusion of cash and potential for future royalty and sales - based payments , we completed a strategic pipeline evaluation focused on determining the optimal value - creating opportunities for our technologies , " said Thomas Kuhn , CEO of Poxel . " Following our recent achievements and a thorough review of the Company's programs , we are excited to announce a new strategic direction for Poxel , with an increasing focus on rare metabolic indications that represents the intersection of high unmet medical needs , promising pre - clinical and clinical data , opinion leader enthusiasm , significant commercial opportunity , and attractive time horizons . Moreover , we believe that by leveraging our existing platforms and proven capabilities to develop products in rare metabolic diseases in addition to NASH , we can be more efficient with our resources and more expediently deliver novel medicines to patients with an even stronger potential to create significant value for the benefit of our shareholders .